The Covid-19 pandemic resulted in an upturn of the economic curve, but for the Pharmaceutical industries, it opened opportunities for innovation, development, and entrance into the market. Beyond this, Pharmaceutical Companies had faced various other issues such as IP waivers put forth by many countries in order to reduce the technical barriers at this time and hold public health over private interests. Pharmaceutical Companies have faced immense problems related to “Patent Cliffs” and have also resorted to “Patent Pools” in order to find a way out of Licensing and IP waivers so as to not harm their IPs and find a way to keep them protected and unexploited by third parties during the Pandemic.